GDANSK (Reuters) -Polish medical laboratory operator Diagnostyka, which listed on the stock exchange in February, reported a second-quarter net profit of 63.8 million zlotys ($17.53 million) on Thursday, driven by rising sales of tests and a higher average price per test.
The company continues its strategy of expanding through acquisitions, particularly in the field of diagnostic imaging. In July, Diagnostyka acquired NZOZ Pracownia Genetyki Nowotworów and a majority stake in VITA-SKAN.
“We are currently engaged in further acquisition discussions with several potential targets. While not every M&A negotiation leads to a deal, we expect to finalise more acquisitions in the medical imaging field this year,” CEO Jakub Swadzba said in a statement.
Diagnostyka said its second-quarter operating revenue rose to 593.4 million zlotys from 591.6 million zlotys reported last quarter.
Its recurring EBITDA for the first half of the year came in at 314.1 million zlotys.
($1 = 3.6405 zlotys)
(Reporting by Julia Kotowska; Editing by Susan Fenton)
Comments